ResearcherNebraska Medical CenterActive in the last 2 years
Virender Kumar
Matched on ORCID iD 0000-0001-5353-5656; OpenAlex author ID A5101629632. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers
Papers 10
- Drug delivery and targeting to chemoresistant pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.216648↗
- Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model. Co-author DOI 10.1038/s41420-024-01920-9↗
- Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. Co-author DOI 10.1016/j.canlet.2023.216462↗
- Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. First author DOI 10.1016/j.jconrel.2020.09.052↗
- Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. First author DOI 10.1126/sciadv.abd6764↗
- Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Co-author DOI 10.1016/j.canlet.2017.05.007↗
- Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-01942-7↗
- EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. First author DOI 10.1021/acs.biomac.5b01419↗
- Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Co-author DOI 10.1021/mp500847s↗
- miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Co-author DOI 10.1016/j.canlet.2012.10.008↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ram I. Mahato · 10 shared papers, 2013–2024 · strength 1.72
- Paper Drug delivery and targeting to chemoresistant pancreatic cancer. DOI 10.1016/j.canlet.2024.216648↗
- Paper Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. DOI 10.1016/j.canlet.2023.216462↗
- Paper Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse … DOI 10.1038/s41420-024-01920-9↗
- Goutam Mondal · 4 shared papers, 2015–2017 · strength 0.30
- Paper Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. DOI 10.1016/j.canlet.2017.05.007↗
- Paper EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. DOI 10.1021/acs.biomac.5b01419↗
- Paper Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. DOI 10.1038/s41598-017-01942-7↗
- Rajan Sharma Bhattarai · 2 shared papers, 2020–2021 · strength 0.25
- Vinod Kumar · 2 shared papers, 2017–2020 · strength 0.19
- Amit Chaudhary · 2 shared papers, 2017 · strength 0.16
- Wěi Li · 1 shared paper, 2021 · strength 0.13
- Tatiana K. Bronich · 1 shared paper, 2021 · strength 0.13
- Xiaofei Xin · 1 shared paper, 2020 · strength 0.12
- Krishna Kattel · 1 shared paper, 2017 · strength 0.09
- Pankaj Kumar Singh · 1 shared paper, 2016 · strength 0.08
- Surendra Kumar Shukla · 1 shared paper, 2016 · strength 0.08
- Surinder K. Batra · 1 shared paper, 2015 · strength 0.06
- Saurabh Pratap Singh · 1 shared paper, 2013 · strength 0.05
- Stephen W. Behrman · 1 shared paper, 2013 · strength 0.05
- Deepak Chitkara · 1 shared paper, 2013 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.